Subgroup analyses and updated overall survival from the phase II trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in metastatic renal cell carcinoma (mRCC) - Hutson, T E; Dutcus, C E; Ren, M (J Clin Oncol, 2016)
(suppl; abstr 4553)